Metabolism, hypoxia and the diabetic heart

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 4, 2011, Pages 598-605

  Heather, Lisa C ^a   Clarke, Kieran ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Diabetes; Heart; HIF; Hypoxia; Metabolism; Mitochondria

Indexed keywords

ADENOSINE TRIPHOSPHATE; FATTY ACID; GLUCOSE; HORMONE; HYPOXIA INDUCIBLE FACTOR; LIPID;

COLLATERAL CIRCULATION; DIABETIC CARDIOMYOPATHY; ENERGY TRANSFER; FATTY ACID METABOLISM; FATTY ACID TRANSPORT; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOLYSIS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HUMAN; LIPID STORAGE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANOXIA; DIABETES MELLITUS; GLUCOSE; HEART; HUMANS; LIPID METABOLISM; MITOCHONDRIA; MYOCARDIUM;

ANIMALIA;

EID: 79952068012     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.01.007     Document Type: Review

References (113)

1. National Health Service - quality and outcomes framework http://www.ic.nhs.uk/statistics-and-data-collections/supporting-information/audits-and-performance/the-quality-and-outcomes-framework/qof-2008/09/data-tables/prevalence-data-tables.
2. Roberts S. Department of Health - turning the corner improving diabetes care http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4136141.
3. McGarry J.D. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51:7-18.
4. Morrish N.J., Wang S.L., Stevens L.K., Fuller J.H., Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001, 44(Suppl 2):S14-S21.
5. Boudina S., Abel E.D. Diabetic cardiomyopathy revisited. Circulation 2007, 115:3213-3223.
6. Scheuermann-Freestone M., Madsen P.L., Manners D., Blamire A.M., Buckingham R.E., Styles P., et al. Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation 2003, 107:3040-3046.
7. How O.J., Aasum E., Severson D.L., Chan W.Y., Essop M.F., Larsen T.S. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. Diabetes 2006, 55:466-473.
8. Buchanan J., Mazumder P.K., Hu P., Chakrabarti G., Roberts M.W., Yun U.J., et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005, 146:5341-5349.
9. Ebert B.L., Firth J.D., Ratcliffe P.J. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem 1995, 270:29083-29089.
10. Semenza G.L., Roth P.H., Fang H.M., Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994, 269:23757-23763.
11. Huss J.M., Levy F.H., Kelly D.P. Hypoxia inhibits the peroxisome proliferator-activated receptor alpha/retinoid X receptor gene regulatory pathway in cardiac myocytes: a mechanism for O2-dependent modulation of mitochondrial fatty acid oxidation. J Biol Chem 2001, 276:27605-27612.
12. Marfella R., Esposito K., Nappo F., Siniscalchi M., Sasso F.C., Portoghese M., et al. Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. Diabetes 2004, 53:2383-2391.
13. Marfella R., D'Amico M., Di Filippo C., Piegari E., Nappo F., Esposito K., et al. Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1. Diabetologia 2002, 45:1172-1181.
14. Taegtmeyer H., Golfman L., Sharma S., Razeghi P., van Arsdall M. Linking gene expression to function: metabolic flexibility in the normal and diseased heart. Ann NY Acad Sci 2004, 1015:202-213.
15. Neely J.R., Rovetto M.J., Oram J.F. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 1972, 15:289-329.
16. Randle P.J., Garland P.B., Hales C.N., Newsholme E.A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963, 1:785-789.
17. Bing R.J., Siegel A., Ungar I., Gilbert M. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. Am J Med 1954, 16:504-515.
18. van der Vusse G.J., Glatz J.F., Stam H.C., Reneman R.S. Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev 1992, 72:881-940.
19. Hauton D., Bennett M.J., Evans R.D. Utilisation of triacylglycerol and non-esterified fatty acid by the working rat heart: myocardial lipid substrate preference. Biochim Biophys Acta 2001, 1533:99-109.
20. Niu Y.G., Hauton D., Evans R.D. Utilization of triacylglycerol-rich lipoproteins by the working rat heart: routes of uptake and metabolic fates. J Physiol 2004, 558:225-237.
21. Augustus A.S., Kako Y., Yagyu H., Goldberg I.J. Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake of TG-derived FA. Am J Physiol Endocrinol Metab 2003, 284:E331-E339.
22. Luiken J.J., Koonen D.P., Willems J., Zorzano A., Becker C., Fischer Y., et al. Insulin stimulates long-chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36. Diabetes 2002, 51:3113-3119.
23. Luiken J.J., Coort S.L., Willems J., Coumans W.A., Bonen A., van der Vusse G.J., et al. Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 2003, 52:1627-1634.
24. Shepherd D., Yates D.W., Garland P.B. The rate-limiting step in the oxidation of palmitate or palmitoyl-coenzyme A by rat-liver mitochondria. Biochem J 1966, 98:3C-4C.
25. Stanley W.C., Meadows S.R., Kivilo K.M., Roth B.A., Lopaschuk G.D. beta-Hydroxybutyrate inhibits myocardial fatty acid oxidation in vivo independent of changes in malonyl-CoA content. Am J Physiol Heart Circ Physiol 2003, 285:H1626-H1631.
26. Hasselbaink D.M., Glatz J.F., Luiken J.J., Roemen T.H., Van der Vusse G.J. Ketone bodies disturb fatty acid handling in isolated cardiomyocytes derived from control and diabetic rats. Biochem J 2003, 371:753-760.
27. Vanoverschelde J.L., Wijns W., Kolanowski J., Bol A., Decoster P.M., Michel C., et al. Competition between palmitate and ketone bodies as fuels for the heart: study with positron emission tomography. Am J Physiol 1993, 264:H701-H707.
28. Little J.R., Goto M., Spitzer J.J. Effect of ketones on metabolism of FFA by dog myocardium and skeletal muscle in vivo. Am J Physiol 1970, 219:1458-1463.
29. Tardif A., Julien N., Pelletier A., Thibault G., Srivastava A.K., Chiasson J.L., et al. Chronic exposure to beta-hydroxybutyrate impairs insulin action in primary cultures of adult cardiomyocytes. Am J Physiol Endocrinol Metab 2001, 281:E1205-E1212.
30. Pelletier A., Coderre L. Ketone bodies alter dinitrophenol-induced glucose uptake through AMPK inhibition and oxidative stress generation in adult cardiomyocytes. Am J Physiol Endocrinol Metab 2007, 292:E1325-E1332.
31. Fischer Y., Thomas J., Rosen P., Kammermeier H. Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats. Endocrinology 1995, 136:412-420.
32. Garland P.B., Randle P.J., Newsholme E.A. Citrate as an intermediary in the inhibition of phosphofructokinase in rat heart muscle by fatty acids, ketone bodies, pyruvate, diabetes, and starvation. Nature 1963, 200:169-170.
33. Bowker-Kinley M.M., Davis W.I., Wu P., Harris R.A., Popov K.M. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 1998, 329(Pt 1):191-196.
34. Kerbey A.L., Randle P.J., Cooper R.H., Whitehouse S., Pask H.T., Denton R.M. Regulation of pyruvate dehydrogenase in rat heart. Mechanism of regulation of proportions of dephosphorylated and phosphorylated enzyme by oxidation of fatty acids and ketone bodies and of effects of diabetes: role of coenzyme A, acetyl-coenzyme A and reduced and oxidized nicotinamide-adenine dinucleotide. Biochem J 1976, 154:327-348.
35. Hansford R.G. Effect of micromolar concentrations of free Ca2+ ions on pyruvate dehydrogenase interconversion in intact rat heart mitochondria. Biochem J 1981, 194:721-732.
36. McCormack J.G., Denton R.M. Role of Ca2+ ions in the regulation of intramitochondrial metabolism in rat heart. Evidence from studies with isolated mitochondria that adrenaline activates the pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase complexes by increasing the intramitochondrial concentration of Ca2+. Biochem J 1984, 218:235-247.
37. Caruso M., Maitan M.A., Bifulco G., Miele C., Vigliotta G., Oriente F., et al. Activation and mitochondrial translocation of protein kinase Cdelta are necessary for insulin stimulation of pyruvate dehydrogenase complex activity in muscle and liver cells. J Biol Chem 2001, 276:45088-45097.
38. Opie L.H. Heart physiology: from cell to circulation 2004, Lippincott, Williams and Wilkins. 4th ed.
39. Reaven G.M., Hollenbeck C., Jeng C.Y., Wu M.S., Chen Y.D. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24h in patients with NIDDM. Diabetes 1988, 37:1020-1024.
40. Niu Y.G., Evans R.D. Myocardial metabolism of triacylglycerol-rich lipoproteins in type 2 diabetes. J Physiol 2009, 587:3301-3315.
41. Avogaro A., Crepaldi C., Miola M., Maran A., Pengo V., Tiengo A., et al. High blood ketone body concentration in type 2 non-insulin dependent diabetic patients. J Endocrinol Invest 1996, 19:99-105.
42. Avogaro A., Nosadini R., Doria A., Fioretto P., Velussi M., Vigorito C., et al. Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease. Am J Physiol 1990, 258:E606-E618.
43. Weinstein A.R., Sesso H.D., Lee I.M., Cook N.R., Manson J.E., Buring J.E., et al. Relationship of physical activity vs body mass index with type 2 diabetes in women. JAMA 2004, 292:1188-1194.
44. Wilding J.P. The importance of free fatty acids in the development of type 2 diabetes. Diabet Med 2007, 24:934-945.
45. Venables M.C., Jeukendrup A.E. Physical inactivity and obesity: links with insulin resistance and type 2 diabetes mellitus. Diabetes Metab Res Rev 2009, 25(Suppl 1):S18-S23.
46. Maffei M., Halaas J., Ravussin E., Pratley R.E., Lee G.H., Zhang Y., et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995, 1:1155-1161.
47. Al-Daghri N., Bartlett W.A., Jones A.F., Kumar S. Role of leptin in glucose metabolism in type 2 diabetes. Diabetes Obes Metab 2002, 4:147-155.
48. Yildiz B.O., Haznedaroglu I.C. Rethinking leptin and insulin action: therapeutic opportunities for diabetes. Int J Biochem Cell Biol 2006, 38:820-830.
49. Hafstad A.D., Solevag G.H., Severson D.L., Larsen T.S., Aasum E. Perfused hearts from type 2 diabetic (db/db) mice show metabolic responsiveness to insulin. Am J Physiol Heart Circ Physiol 2006, 290:H1763-H1769.
50. Peterson L.R., Herrero P., Schechtman K.B., Racette S.B., Waggoner A.D., Kisrieva-Ware Z., et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 2004, 109:2191-2196.
51. Luiken J.J., Arumugam Y., Bell R.C., Calles-Escandon J., Tandon N.N., Glatz J.F., et al. Changes in fatty acid transport and transporters are related to the severity of insulin deficiency. Am J Physiol Endocrinol Metab 2002, 283:E612-E621.
52. Carley A.N., Atkinson L.L., Bonen A., Harper M.E., Kunnathu S., Lopaschuk G.D., et al. Mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db/db mice. Arch Physiol Biochem 2007, 113:65-75.
53. Schwenk R.W., Dirkx E., Coumans W.A., Bonen A., Klip A., Glatz J.F., et al. Requirement for distinct vesicle-associated membrane proteins in insulin- and AMP-activated protein kinase (AMPK)-induced translocation of GLUT4 and CD36 in cultured cardiomyocytes. Diabetologia 2010, 53(10):2209-2219.
54. Sharma S., Adrogue J.V., Golfman L., Uray I., Lemm J., Youker K., et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004, 18:1692-1700.
55. Zhou Y.T., Grayburn P., Karim A., Shimabukuro M., Higa M., Baetens D., et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000, 97:1784-1789.
56. Avogaro A., Vigili de Kreutzenberg S., Negut C., Tiengo A., Scognamiglio R. Diabetic cardiomyopathy: a metabolic perspective. Am J Cardiol 2004, 93:13A-16A.
57. Stanley W.C., Lopaschuk G.D., McCormack J.G. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997, 34:25-33.
58. Sato K., Kashiwaya Y., Keon C.A., Tsuchiya N., King M.T., Radda G.K., et al. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J 1995, 9:651-658.
59. Mazumder P.K., O'Neill B.T., Roberts M.W., Buchanan J., Yun U.J., Cooksey R.C., et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004, 53:2366-2374.
60. Jagasia D., Whiting J.M., Concato J., Pfau S., McNulty P.H. Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation 2001, 103:1734-1739.
61. Bugger H., Abel E.D. Rodent models of diabetic cardiomyopathy. Dis Model Mech 2009, 2:454-466.
62. Chen D., Wang M.W. Development and application of rodent models for type 2 diabetes. Diabetes Obes Metab 2005, 7:307-317.
63. Seymour A.M., Chatham J.C. The effects of hypertrophy and diabetes on cardiac pyruvate dehydrogenase activity. J Mol Cell Cardiol 1997, 29:2771-2778.
64. Schroeder M.A., Cochlin L.E., Heather L.C., Clarke K., Radda G.K., Tyler D.J. In vivo assessment of pyruvate dehydrogenase flux in the heart using hyperpolarized carbon-13 magnetic resonance. Proc Natl Acad Sci USA 2008, 105:12051-12056.
65. Hall J.L., Stanley W.C., Lopaschuk G.D., Wisneski J.A., Pizzurro R.D., Hamilton C.D., et al. Impaired pyruvate oxidation but normal glucose uptake in diabetic pig heart during dobutamine-induced work. Am J Physiol 1996, 271:H2320-H2329.
66. Katzen H.M., Soderman D.D., Wiley C.E. Multiple forms of hexokinase. Activities associated with subcellular particulate and soluble fractions of normal and streptozotocin diabetic rat tissues. J Biol Chem 1970, 245:4081-4096.
67. Thompson A.L., Cooney G.J. Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance. Diabetes 2000, 49:1761-1765.
68. Desrois M., Sidell R.J., Gauguier D., King L.M., Radda G.K., Clarke K. Initial steps of insulin signaling and glucose transport are defective in the type 2 diabetic rat heart. Cardiovasc Res 2004, 61:288-296.
69. Menard S.L., Croteau E., Sarrhini O., Gelinas R., Brassard P., Ouellet R., et al. Abnormal in vivo myocardial energy substrate uptake in diet-induced type 2 diabetic cardiomyopathy in rats. Am J Physiol Endocrinol Metab 2010, 298(5):E1049-E1057.
70. Lajoie C., Beliveau L., Trudeau F., Lavoie N., Massicotte G., Gagnon S., et al. The rapid onset of hyperglycaemia in ZDF rats was associated with a widespread alteration of metabolic proteins implicated in glucose metabolism in the heart. Can J Physiol Pharmacol 2006, 84:1205-1213.
71. Deng J.Y., Huang J.P., Lu L.S., Hung L.M. Impairment of cardiac insulin signaling and myocardial contractile performance in high-cholesterol/fructose-fed rats. Am J Physiol Heart Circ Physiol 2007, 293:H978-H987.
72. Tabbi-Anneni I., Buchanan J., Cooksey R.C., Abel E.D. Captopril normalizes insulin signaling and insulin-regulated substrate metabolism in obese (ob/ob) mouse hearts. Endocrinology 2008, 149:4043-4050.
73. Monti L.D., Landoni C., Setola E., Galluccio E., Lucotti P., Sandoli E.P., et al. Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in Type 2 diabetic patients. Am J Physiol Heart Circ Physiol 2004, 287:H1225-H1231.
74. Chiu H.C., Kovacs A., Blanton R.M., Han X., Courtois M., Weinheimer C.J., et al. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 2005, 96:225-233.
75. Finck B.N., Lehman J.J., Leone T.C., Welch M.J., Bennett M.J., Kovacs A., et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002, 109:121-130.
76. How O.J., Larsen T.S., Hafstad A.D., Khalid A., Myhre E.S., Murray A.J., et al. Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice. Arch Physiol Biochem 2007, 113:211-220.
77. Sidell R.J., Cole M.A., Draper N.J., Desrois M., Buckingham R.E., Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker fatty rat heart. Diabetes 2002, 51:1110-1117.
78. Yu C., Chen Y., Cline G.W., Zhang D., Zong H., Wang Y., et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002, 277:50230-50236.
79. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
80. Dabkowski E.R., Baseler W.A., Williamson C.L., Powell M., Razunguzwa T.T., Frisbee J.C., et al. Mitochondrial dysfunction in the type 2 diabetic heart is associated with alterations in spatially distinct mitochondrial proteomes. Am J Physiol Heart Circ Physiol 2010, 299:H529-H540.
81. Kuo T.H., Moore K.H., Giacomelli F., Wiener J. Defective oxidative metabolism of heart mitochondria from genetically diabetic mice. Diabetes 1983, 32:781-787.
82. Boudina S., Sena S., Theobald H., Sheng X., Wright J.J., Hu X.X., et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007, 56:2457-2466.
83. Anderson E.J., Kypson A.P., Rodriguez E., Anderson C.A., Lehr E.J., Neufer P.D. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol 2009, 54:1891-1898.
84. Palmer J.W., Tandler B., Hoppel C.L. Biochemical properties of subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle. J Biol Chem 1977, 252:8731-8739.
85. Ivanovic-Matic S., Mihailovic M., Dinic S., Martinovic V., Bogojevic D., Grigorov I., et al. The absence of cardiomyopathy is accompanied by increased activities of CAT, MnSOD and GST in long-term diabetes in rats. J Physiol Sci 2010, 60(4):259-266.
86. Bhamra G.S., Hausenloy D.J., Davidson S.M., Carr R.D., Paiva M., Wynne A.M., et al. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 2008, 103:274-284.
87. Boardman N., Hafstad A.D., Larsen T.S., Severson D.L., Aasum E. Increased O2 cost of basal metabolism and excitation-contraction coupling in hearts from type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2009, 296:H1373-H1379.
88. Murray A.J., Panagia M., Hauton D., Gibbons G.F., Clarke K. Plasma free fatty acids and peroxisome proliferator-activated receptor alpha in the control of myocardial uncoupling protein levels. Diabetes 2005, 54:3496-3502.
89. Chou E., Suzuma I., Way K.J., Opland D., Clermont A.C., Naruse K., et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002, 105:373-379.
90. Iyer N.V., Leung S.W., Semenza G.L. The human hypoxia-inducible factor 1alpha gene: HIF1A structure and evolutionary conservation. Genomics 1998, 52:159-165.
91. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008, 30:393-402.
92. Wang G.L., Semenza G.L. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993, 90:4304-4308.
93. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16:4604-4613.
94. Chan S.Y., Zhang Y.Y., Hemann C., Mahoney C.E., Zweier J.L., Loscalzo J. MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab 2009, 10:273-284.
95. Fukuda R., Zhang H., Kim J.W., Shimoda L., Dang C.V., Semenza G.L. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007, 129:111-122.
96. Cai Z., Zhong H., Bosch-Marce M., Fox-Talbot K., Wang L., Wei C., et al. Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc Res 2008, 77:463-470.
97. Yu A.Y., Shimoda L.A., Iyer N.V., Huso D.L., Sun X., McWilliams R., et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest 1999, 103:691-696.
98. Huang Y., Hickey R.P., Yeh J.L., Liu D., Dadak A., Young L.H., et al. Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J 2004, 18:1138-1140.
99. Jesmin S., Zaedi S., Shimojo N., Iemitsu M., Masuzawa K., Yamaguchi N., et al. Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts. Am J Physiol Endocrinol Metab 2007, 292:E1030-E1040.
100. Ebrahimian T.G., Heymes C., You D., Blanc-Brude O., Mees B., Waeckel L., et al. NADPH oxidase-derived overproduction of reactive oxygen species impairs postischemic neovascularization in mice with type 1 diabetes. Am J Pathol 2006, 169:719-728.
101. Heinis M., Simon M.T., Ilc K., Mazure N.M., Pouyssegur J., Scharfmann R., et al. Oxygen tension regulates pancreatic beta-cell differentiation through hypoxia-inducible factor 1alpha. Diabetes 2010, 59:662-669.
102. Gunton J.E., Kulkarni R.N., Yim S., Okada T., Hawthorne W.J., Tseng Y.H., et al. Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell 2005, 122:337-349.
103. Cantley J., Selman C., Shukla D., Abramov A.Y., Forstreuter F., Esteban M.A., et al. Deletion of the von Hippel-Lindau gene in pancreatic beta cells impairs glucose homeostasis in mice. J Clin Invest 2009, 119:125-135.
104. Wang P., Lloyd S.G., Zeng H., Bonen A., Chatham J.C. Impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 2005, 288:H2102-H2110.
105. Aasum E., Hafstad A.D., Severson D.L., Larsen T.S. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes 2003, 52:434-441.
106. Taniguchi Y., Ooie T., Takahashi N., Shinohara T., Nakagawa M., Yonemochi H., et al. Pioglitazone but not glibenclamide improves cardiac expression of heat shock protein 72 and tolerance against ischemia/reperfusion injury in the heredity insulin-resistant rat. Diabetes 2006, 55:2371-2378.
107. Yue T.L., Bao W., Gu J.L., Cui J., Tao L., Ma X.L., et al. Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005, 54:554-562.
108. Wang P., Chatham J.C. Onset of diabetes in Zucker diabetic fatty (ZDF) rats leads to improved recovery of function after ischemia in the isolated perfused heart. Am J Physiol Endocrinol Metab 2004, 286:E725-E736.
109. Lehto S., Pyorala K., Miettinen H., Ronnemaa T., Palomaki P., Tuomilehto J., et al. Myocardial infarct size and mortality in patients with non-insulin-dependent diabetes mellitus. J Intern Med 1994, 236:291-297.
110. Saker F., Ybarra J., Leahy P., Hanson R.W., Kalhan S.C., Ismail-Beigi F. Glycemia-lowering effect of cobalt chloride in the diabetic rat: role of decreased gluconeogenesis. Am J Physiol 1998, 274:E984-E991.
111. Yildirim O., Buyukbingol Z. Effects of supplementation with a combination of cobalt and ascorbic acid on antioxidant enzymes and lipid peroxidation levels in streptozocin-diabetic rat liver. Biol Trace Elem Res 2002, 90:143-154.
112. Dioum E.M., Chen R., Alexander M.S., Zhang Q., Hogg R.T., Gerard R.D., et al. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science 2009, 324:1289-1293.
113. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450:712-716.